Post-marketing Surveillance to Evaluate the Safety and Effectiveness of Upadacitinib (RINVOQ) in Korean Adult Patients With Ulcerative Colitis or Crohn's Disease
Latest Information Update: 17 Dec 2024
At a glance
- Drugs Upadacitinib (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions
- Sponsors AbbVie
Most Recent Events
- 13 Dec 2024 Planned End Date changed from 31 Dec 2025 to 1 Dec 2025.
- 13 Dec 2024 Planned primary completion date changed from 31 Dec 2025 to 1 Dec 2025.
- 09 Jul 2024 Status changed from not yet recruiting to recruiting.